To the full analysis
Arrowhead Pharmaceuticals stock: growth
ARWRArrowhead Pharmaceuticals reported $450.82M in revenue for fiscal 2026, down 45.6% on the prior year, up 26.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
36.6%
per year from 2007 to 2026, per share 12.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 26.7% | 121.5% | 36.6% |
| Revenue per share | 19.0% | 103.6% | 12.5% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $1.21M | −$29.93M | −$24.62M |
| 2008 | $1.3M | −$27.09M | −$28.27M |
| 2009 | $3.76M | −$19.31M | −$15.32M |
| 2010 | $620.1K | −$5.77M | −$7.7M |
| 2011 | $296.14K | −$3.13M | −$5.4M |
| 2012 | $146.88K | −$21.13M | −$15.82M |
| 2013 | $290.27K | −$31.14M | −$19.33M |
| 2014 | $175K | −$58.63M | −$37.13M |
| 2015 | $382K | −$91.94M | −$67.68M |
| 2016 | $158.33K | −$81.72M | −$68.29M |
| 2017 | $31.41M | −$34.38M | −$31.86M |
| 2018 | $16.14M | −$54.45M | −$48.64M |
| 2019 | $168.8M | $67.98M | $161.03M |
| 2020 | $87.99M | −$84.55M | −$107.75M |
| 2021 | $138.29M | −$140.85M | $147.75M |
| 2022 | $243.23M | −$176.06M | −$188.91M |
| 2023 | $240.74M | −$205.28M | −$330.63M |
| 2024 | $3.55M | −$599.49M | −$604.32M |
| 2025 | $829.45M | −$1.63M | $156.89M |
| 2026 | $450.82M | −$724.21M | −$283.94M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 8 May 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.